What is the proper administration method and dosage of L‑ornithine‑L‑aspartate (LOLA) injection for adult patients with hepatic encephalopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Administration of Intravenous L-Ornithine-L-Aspartate (LOLA)

Administer LOLA as a continuous intravenous infusion at 30 g per day, dissolved in 250 mL of 5% fructose or compatible solution, infused over 24 hours for 5 consecutive days in patients with overt hepatic encephalopathy. 1

Dosing and Preparation

  • Standard dose: 30 g daily via continuous IV infusion 1, 2
  • Alternative regimen: 20 g daily dissolved in 250 mL of 5% fructose, infused over 4 hours for 7 consecutive days (used in earlier trials, though 30 g/day is now standard) 3
  • Duration: Typically 5 days, though some protocols extend to 7 days 4, 3

Clinical Context and Patient Selection

LOLA is most effective in mild-to-moderate hepatic encephalopathy (West-Haven grade 1-2) and should be used as adjunctive therapy combined with lactulose, not as monotherapy. 1, 2

When to Use LOLA:

  • Overt hepatic encephalopathy grade 1-2: LOLA demonstrates superior efficacy in lowering ammonia levels and improving psychometric test performance compared to placebo 1, 3
  • Severe encephalopathy (grade 3-4): Recent high-quality evidence shows LOLA combined with lactulose and rifaximin achieves 92.5% improvement in HE grade versus 66% with lactulose/rifaximin alone (p < 0.001), with significantly lower 28-day mortality (16.4% vs 41.8%, p = 0.001) 5
  • Accelerated recovery: LOLA shortens time to recovery from 2.50 days to 1.92 days when added to standard therapy (p = 0.002) 4, 2

When NOT to Use LOLA:

  • Acute liver failure: A large randomized trial (n=201) showed LOLA did not reduce mortality (42.4% vs 33.3% placebo, p = 0.204) or lower ammonia levels in acute liver failure 6
  • Oral route for overt HE: Oral LOLA can lower ammonia but lacks sufficient evidence for managing overt encephalopathy; further studies are needed 1

Mechanism of Action

LOLA works through dual ammonia-lowering pathways 1, 2:

  • Urea synthesis: Ornithine serves as a substrate for the urea cycle in hepatocytes
  • Glutamine synthesis: Aspartate promotes glutamine formation via glutamine synthetase, particularly in muscle tissue
  • Additional effects: Reduces inflammatory markers (IL-6, TNF-α) beyond ammonia reduction 5

Integration with Standard Therapy

Always combine LOLA with first-line lactulose therapy; the combination is superior to either agent alone. 2, 5, 4

Treatment Algorithm:

  1. Initiate lactulose: 20-30 g (30-45 mL) orally 3-4 times daily, titrated to 2-3 soft stools per day 1
  2. Add rifaximin: 400 mg three times daily or 550 mg twice daily for recurrent or inadequate response 1
  3. Add IV LOLA: 30 g/day continuous infusion for patients requiring accelerated recovery or with grade 3-4 encephalopathy 2, 5
  4. Consider albumin: 1.5 g/kg/day for grade ≥2 encephalopathy until improvement or maximum 10 days 1, 2

Monitoring and Expected Outcomes

  • Ammonia levels: Measure daily during infusion; expect significant reductions by day 5 5, 4, 3
  • Mental status: Assess HE grade daily using West-Haven criteria; improvement typically occurs within 1-4 days 4, 2
  • Recovery time: Mean time to recovery is approximately 1.9 days with LOLA versus 2.5 days without 4, 2

Safety Profile

LOLA demonstrates excellent safety with minimal adverse effects. 3

  • Adverse events: Mild gastrointestinal disturbances in approximately 5% of patients 3
  • No serious toxicity: No nephrotoxicity, ototoxicity, or peripheral neuropathy (unlike neomycin or metronidazole) 1
  • Contraindications: Avoid in acute liver failure based on lack of efficacy 6

Common Pitfalls to Avoid

  • Using LOLA as monotherapy: Always combine with lactulose; LOLA is adjunctive, not a replacement for standard therapy 2, 5, 4
  • Oral LOLA for acute overt HE: Insufficient evidence supports oral formulation for acute management; reserve IV route for overt encephalopathy 1
  • Expecting benefit in acute liver failure: LOLA is ineffective in this population and should not be used 6
  • Inadequate infusion duration: Ensure continuous 24-hour infusion rather than bolus dosing to maintain steady ammonia-lowering effect 5, 4

References

2
Guideline

Guidelines for Ammonia‑Lowering Therapy in Hepatic Encephalopathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the recommended dose of L-ornithine-L-aspartate (LOLA) for chronic or sub-clinical hepatic encephalopathy and for acute overt hepatic encephalopathy?
How should L‑ornithine‑L‑aspartate (LOLA) be given by intravenous infusion in adults with hepatic encephalopathy?
What is the appropriate dose and administration schedule of intravenous L‑ornithine‑L‑aspartate (LOLA) for a patient with Grade III hepatic encephalopathy?
How should Hepa-Merz (L-ornithine-L-aspartate) be dosed and administered in a patient with grade 4 hepatic encephalopathy?
Is it safe to administer intravenous L-ornithine‑L‑aspartate (LOLA) 30 g in 60 mL over 24 hours?
What is the recommended follow‑up schedule after a radical nephrectomy with negative margins and pathologic stage pT3aN0M0 according to the American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) guidelines?
In a 65-year-old woman with newly diagnosed diabetes who has been started on metformin and now has an HbA1c of 55 mmol/mol (5.5 %), when should the HbA1c be repeated and the medication reviewed?
For how long should antiepileptic drug therapy be continued in a patient with a calcified neurocysticercosis granuloma who has become seizure‑free?
What does a narrow callosal angle on coronal MRI indicate in normal‑pressure hydrocephalus?
What are the International Continence Society (ICS) guidelines for uroflowmetry paper trace?
In a patient on a non‑taperable corticosteroid with clinically significant anxiety, should mirtazapine be started and what is the recommended dosing and monitoring?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.